Gut Microbes and the High-Fat Diet: A Recipe for Colorectal Cancer?
Colorectal cancer (CRC) is a serious health concern, ranking as the third leading cause of cancer-related deaths in men and the fourth in women in the U.S. as of 2024. The rates of CRC are also on the rise among young adults, increasing by about 2.4% each year from 2012 to 2021. Obesity is one of the key factors driving this trend. But what's the connection between gut microbes and this alarming increase in CRC cases?
A recent study published in the Journal of Biological Chemistry sheds light on this complex relationship. Researchers found that a high-fat diet, similar to a fast-food-heavy human diet, boosts ammonia-producing bacteria in the gut microbiome. This, in turn, promotes the development of CRC in mice. The study, led by Lopa Mishra and Krishanu Bhowmick at the Feinstein Institutes for Medical Research, reveals a surprising connection between gut microbes and a critical cancer pathway.
The Transforming Growth Factor Beta (TGF-β) Signaling Pathway
TGF-β signaling typically plays a crucial role in cancer. In the early stages, it suppresses tumor growth, but later on, it can promote it. Mishra's team previously demonstrated that disrupting TGF-β signaling leads to the development of CRC and other gastrointestinal cancers in mice. Interestingly, studies have shown that TGF-β deficiency does not trigger tumors in mice lacking a microbiome, and that microbiome-induced increases in ammonia levels can promote CRC. This suggests that ammonia, produced by the gut microbiome, may help tumors outcompete healthy tissue, as normal cells cannot tolerate high ammonia levels.
The Discovery: Microbial Metabolites Targeting TGF-β
The researchers discovered that ammonia interacts with the N-terminus of βII-spectrin (SPTBN1), a downstream component of the TGF-β pathway. This interaction disrupts the normal function of SPTBN1, which typically promotes tumor suppression by interacting with SMAD3 in the nucleus. Ammonia traps SMAD3 at the cell membrane and in the cytoplasm, hindering its ability to suppress tumor growth. When the team depleted SPTBN1, they restored SMAD3 activation, nuclear localization, and tumor suppression functions.
The Impact: A New Understanding of CRC Treatment
Mishra emphasizes the significance of this discovery, stating that it demonstrates how a major signaling pathway like TGF-β can be targeted by microbial metabolites. Bhowmick adds that this finding clarifies the role of a specific signaling pathway in mediating ammonia toxicity in CRC. The team's findings suggest that inhibiting βII-spectrin could restore normal signaling and slow disease progression, making it a promising molecular target for CRC therapy.
The study highlights the intricate relationship between gut microbes, diet, and cancer. While it's crucial to remember that these findings are based on mouse models, they offer valuable insights into the potential mechanisms driving CRC. Further research is needed to explore the implications of these findings in humans and to develop effective therapeutic strategies.
